Sequence enrichment profiles enable target-agnostic antibody generation for a broad range of antigens.

ABSTRACT: Phenotypic drug discovery (PDD) enables the target-agnostic generation of therapeutic drugs with novel mechanisms of action. However, realizing its full potential for biologics discovery requires new technologies to produce antibodies to all, a priori unknown, disease-associated biomolecules. We present a methodology that helps achieve this by integrating computational modeling, differential antibody display selection, and massive parallel sequencing. The method uses the law of mass action-based computational modeling to optimize antibody display selection and, by matching computationally modeled and experimentally selected sequence enrichment profiles, predict which antibody sequences encode specificity for disease-associated biomolecules. Applied to a phage display antibody librar

SUBMITTER: Mattsson J 

PROVIDER: S-EPMC10261905 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature